On October 31, the “2019 Summit Forum on Improving the Quality of Listed Companies and the 21st Golden Bull Award of Listed Companies” hosted by China Securities Journal was held in Beijing. Based on its outstanding performance growth, healthy financial status, and continuous innovation ability, Hybribio has been awarded the Golden Bull Award of the Listed Companies “Top 100 Most Valuable Investment”.

Forum scene

Vice General Manager of Hybribio, Zhisheng Guan (6th from the left), took the prize

The “Golden Bull Award” has been successfully held for 21 times so far. It is a financial brand created by the China Securities Journal. It has witnessed the rapid development of the Chinese capital market and has become one of the most influential awards in the Chinese capital market. Compared with previous years, this year’s selection has a wider range of selection, a larger number of selection samples, and higher evaluation standards. Furthermore, the selection of the “Golden Bull – The Most Investment Value Award” is more inclined to comprehensively consider the capabilities of corporate profitability, debt service, asset management and growth. It is the “performance backbone” of all awards, with the heaviest weight. The successful selection of Hybribio is the great demonstration of its outstanding main performance and obvious brand advantage.

Since its listing, Hybribio has achieved all-round growth from performance, net profit, taxation, to brand value and the team, and has been unanimously recognized by the government, shareholders, partners and society. With the national policy of two-cancer screening popularizes, the development of HPV detection technology and consumption upgrading jointly promote the continuous growth of HPV detection industry. In the past six years, Hybribio’s performance in the areas of maternal and child health and birth defects, thalassemia, deafness, and reproductive tract infections has grown steadily. Its products have been widely used in clinical diagnosis, large-scale population screening, and eugenics. In 2019, Hybribio implemented the “Nucleic Acid 99 Strategy” to optimize the product structure and strive to maximize the market expansion of nucleic acid detection products. With the advantage of molecular testing, 25 medical laboratories were deployed nationwide to provide medical testing with integrated diagnostic solutions service. The synergy development of products and services has established Hybribio as a leader in nucleic acid molecular diagnostics.

The “Golden Bull Award – Top 100 Most Valuable Investment” of the listed company not only fully affirmed Hybribio’s standardized operation and stable development, but also showed that its investment value is being widely recognized by investors and review experts. Looking forward to the future, Hybribo will continuously improve the output and transformation of scientific and technological innovation, and be a source of industry innovation. With the concept of “trustworthy quality, scientific management”, Hybribio will continue to improve the quality of products and services, and lead the benign and innovative development of the industry. Meanwhile, Hybribio will stick to the market development, further improve corporate management, and continuously contribute to the sustainable development of the biomedical industry.